Cargando…

Pharmacokinetics of Meropenem in People with Cystic Fibrosis—A Proof of Concept Clinical Trial

Anti-infective treatment of pulmonary exacerbations is a major issue in people with cystic fibrosis (CF). Individualized dosing strategies and adaptation of infusion times are important concepts to optimize anti-infective therapy. In this prospective non-randomized controlled open-label trial, we co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamp, Jan C., Fuge, Jan, Ringshausen, Felix C., Grote-Koska, Denis, Brand, Korbinian, Graalmann, Lukas, Vonberg, Ralf-Peter, Welte, Tobias, Rademacher, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998425/ https://www.ncbi.nlm.nih.gov/pubmed/33799542 http://dx.doi.org/10.3390/antibiotics10030292

Ejemplares similares

C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
por: Pink, Isabell, et al.
Publicado: (2021)

Computed Tomography in Adults with Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease: Typical Imaging Findings
por: Dettmer, Sabine, et al.
Publicado: (2021)

Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis
por: Rademacher, Jessica, et al.
Publicado: (2023)

Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
por: Dettmer, Sabine, et al.
Publicado: (2023)

Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings
por: Dettmer, Sabine, et al.
Publicado: (2018)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Assessment of a Mobile App by Adolescents and Young Adults With Cystic Fibrosis: Pilot Evaluation
por: Rudolf, Isa, et al.
Publicado: (2019)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and Trends
por: Ringshausen, Felix C., et al.
Publicado: (2013)

Technical Note: First Use of Endonasal Confocal Laser Endomicroscopy – Feasibility and Proof of Concept
por: Wenda, Nina, et al.
Publicado: (2021)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Clinical and Microbiological Effects of an Antimicrobial Stewardship Program in Urology—A Single Center Before-After Study
por: Joean, Oana, et al.
Publicado: (2022)

Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation
por: Song, Xiangqing, et al.
Publicado: (2019)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
por: Braune, Stephan, et al.
Publicado: (2018)

Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge
por: Honore, Patrick M., et al.
Publicado: (2015)

Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support
por: Zylbersztajn, Brenda, et al.
Publicado: (2021)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
por: Deng, Guoliang, et al.
Publicado: (2023)

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
por: Trang, M., et al.
Publicado: (2021)

COVID-19 in lung transplant recipients—Risk prediction and outcomes
por: Kamp, Jan C., et al.
Publicado: (2021)

The Versatile Transceiver Proof of Concept
por: Troska, J, et al.
Publicado: (2009)

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009–2014
por: Ringshausen, Felix C., et al.
Publicado: (2016)

Pharmacokinetics of meropenem in intensive care patients receiving continuous renal replacement therapy
por: Giles, LJ, et al.
Publicado: (1998)

Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
por: Goncalves-Pereira, João, et al.
Publicado: (2014)

Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial
por: Rodriguez-Miguelez, Paula, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept
por: Scott, Catherine J, et al.
Publicado: (2018)

611. Meropenem Dosage Optimization in Critically Ill Patients Based on a Population Pharmacokinetic Approach.
por: Romano-Aguilar, Melissa, et al.
Publicado: (2022)

SHERPA 1.alpha, a proof-of-concept version
por: Gleisberg, Tanju, et al.
Publicado: (2003)

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
por: Sime, Fekade B., et al.
Publicado: (2018)

Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis: An animal study
por: Hanberg, Pelle, et al.
Publicado: (2019)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
por: Drick, Nora, et al.
Publicado: (2018)

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2022)

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
por: Drick, Nora, et al.
Publicado: (2023)

Why do some adults with PiMZ α(1)-antitrypsin develop bronchiectasis?
por: Aggarwal, Nupur, et al.
Publicado: (2016)

Conventional vs. Tablet Computer-Based Patient Education following Lung Transplantation – A Randomized Controlled Trial
por: Suhling, Hendrik, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gg6jco2fampki6ckinf053h1h2